The week in pharma: action, reaction and insight – week to May 3, 2024
By Barbara Obstoj-Cardwell. Editor
M&A news featured again last week, first with Japan’s Ono Pharmaceutical announcing a $2.4 billion takeover of US oncology focused Deciphera Pharmaceuticals, and then Swiss pharma giant Novartis revealing that is acquiring US biotech start-up Mariana Oncology for up to $1.75 billion to expand its radioligand therapy portfolio. Also of note, Italy’s Newron Pharmaceuticals released positive new Phase II/III data for its schizophrenia candidate evenamide. And, US pharma giant Pfizer presented strong first-quarter 2024 financial results, despite significant loss of revenue from covid-related products.
Ono Pharma to acquire Deciphera
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze